MKENA.COM CAN BE FUN FOR ANYONE

CDER’s latest proposal to withdraw the accelerated acceptance of Makena (HPC) was dependent on a sizable randomized trial that failed to substantiate the advantage of this drug to newborns or minimize the risk of PTB. In producing the decision to suggest Makena’s withdrawal, CDER also reviewed results from prior experiments of progestins (HPC